Format

Send to

Choose Destination
Am J Obstet Gynecol. 2010 Oct;203(4):347.e1-6. doi: 10.1016/j.ajog.2010.04.019. Epub 2010 Jul 1.

Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients.

Author information

1
Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.

Abstract

OBJECTIVE:

To determine the clinicopathologic factors associated with survival in neuroendocrine small cell cervical cancer patients.

STUDY DESIGN:

Patients were identified from a review of literature with an additional 52 patients from four hospitals. Kaplan-Meier and Cox regression methods were used for analyses.

RESULTS:

Of 188 patients, 135 had stages I-IIA, 45 stages IIB-IVA, and 8 stage IVB disease. A total of 55.3% underwent surgery, 16.0% had chemoradiation, 12.8% radiation, and 3.2% chemotherapy alone. The 5-year disease-specific survival in stage I-IIA, IIB-IVA, and IVB disease was 36.8%, 9.8%, and 0%, respectively (P < .001). Adjuvant chemotherapy or chemoradiation was associated with improved survival in patients with stages IIB-IVA disease compared with those who did not receive chemotherapy (17.8% vs 6.0%; P = .04). On multivariable analysis, early-stage disease and use of chemotherapy or chemoradiation were independent prognostic factors for improved survival.

CONCLUSION:

Use of adjuvant chemotherapy or chemoradiation was associated with higher survival in small cell cervical cancer patients.

PMID:
20579961
DOI:
10.1016/j.ajog.2010.04.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center